Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice

Journal of Immunology

Volumn 183, Issue 11, 2009, Pages 7411-7419

  Frazier, W Joshua ^a,b   Wang, Xianxi ^a   Wancket, Lyn M ^c   Li, Xiang An ^d   Meng, Xiaomei ^a   Nelin, Leif D ^a,b   Cato, Andrew C B ^e   Liu, Yusen ^a,b,c  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GENTAMICIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; DUSP1 PROTEIN, MOUSE; GLUCOSE; GLYCOGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENERGY; ESCHERICHIA COLI; GENE DELETION; GRAM NEGATIVE SEPSIS; HISTOPATHOLOGY; INFLAMMATION; LIGATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUNCTURE; SEPTIC SHOCK; SURVIVAL; ANIMAL; BIOSYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTION; GRAM NEGATIVE INFECTION; HYPERLIPIDEMIA; IMMUNOLOGY; LIPID METABOLISM; METABOLISM; MICROBIOLOGY; MOUSE MUTANT; SEPSIS;

ANIMALS; CYCLOOXYGENASE 2; DUAL SPECIFICITY PHOSPHATASE 1; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GLUCOSE; GLYCOGEN; GRAM-NEGATIVE BACTERIAL INFECTIONS; HYPERLIPIDEMIAS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; LIPID METABOLISM; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73349120613     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0804343     Document Type: Article

References (54)

1. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29: 1303-1310.
2. Angus, D. C., and R. S. Wax. 2001. Epidemiology of sepsis: an update. Crit. Care Med. 29: S109-S116.
3. Hotchkiss, R. S., and I. E. Karl. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348: 138-150.
4. Beutler, B. 1995. TNF, immunity and inflammatory disease: lessons of the past decade. J. Investig. Med. 43: 227-235.
5. Beutler, B., and F. Bazzoni. 1998. TNF, apoptosis and autoimmunity: a common thread? Blood Cells. Mol. Dis. 24: 216-230.
6. O'Shea, J. J., A. Ma, and P. Lipsky. 2002. Cytokines and autoimmunity. Nat. Rev. Immunol. 2: 37-45.
7. Janeway, J., A. Charles, P. Travers, M. Walport, and M. J. Schlomchik. 2005. Immunobiology: the immune system in health and disease. Garland Science, New York.
8. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature 420: 885-891.
9. Fisher, C. J., Jr., J. M. Agosti, S. M. Opal, S. F. Lowry, R. A. Balk, J. C. Sadoff, E. Abraham, R. M. Schein, and E. Benjamin. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334: 1697-1702.
10. Parrillo, J. E. 1993. Pathogenetic mechanisms of septic shock. N. Engl. J. Med. 328: 1471-1477.
11. Spiller, S., G. Elson, R. Ferstl, S. Dreher, T. Mueller, M. Freudenberg, B. Daubeuf, H. Wagner, and C. J. Kirschning. 2008. TLR4-induced IFN-γ production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J. Exp. Med. 205: 1747-1754.
12. Liu, Y., E. G. Shepherd, and L. D. Nelin. 2007. MAPK phosphatases - regulating the immune response. Nat. Rev. Immunol. 7: 202-212.
13. Wu, J. J., and A. M. Bennett. 2005. Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling. J. Biol. Chem. 280: 16461-16466.
14. Beutler, B. 2000. Tlr4: central component of the sole mammalian LPS sensor. Curr. Opin. Immunol. 12: 20-26.
15. Klebanoff, S. J. 2005. Myeloperoxidase: friend and foe. J. Leukocyte Biol. 77: 598-625.
16. Serbina, N. V., T. P. Salazar-Mather, C. A. Biron, W. A. Kuziel, and E. G. Pamer. 2003. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19: 59-70.
17. Plank, L. D., A. B. Connolly, and G. L. Hill. 1998. Sequential changes in the metabolic response in severely septic patients during the first 23 days after the onset of peritonitis. Ann. Surg. 228: 146-158.
18. Trager, K., D. DeBacker, and P. Radermacher. 2003. Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr. Opin. Crit. Care 9: 271-278.
19. Harris, H. W., J. E. Gosnell, and Z. L. Kumwenda. 2000. The lipemia of sepsis: triglyceride-rich lipoproteins as agents of innate immunity. J Endotoxin Res. 6: 421-430.
20. Kattan, O. M., F. B. Kasravi, E. L. Elford, M. T. Schell, and H. W. Harris. 2008. Apolipoprotein E-mediated immune regulation in sepsis. J. Immunol. 181: 1399-1408.
21. Wang, X., X. Meng, J. R. Kuhlman, L. D. Nelin, K. K. Nicol, B. K. English, and Y. Liu. 2007. Knockout of Mkp-1 enhances the host inflammatory responses to Gram-positive bacteria. J. Immunol. 178: 5312-5320.
22. Zhao, Q., E. G. Shepherd, M. E. Manson, L. D. Nelin, A. Sorokin, and Y. Liu. 2005. The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. J. Biol. Chem. 280: 8101-8108.
23. Zhao, Q., X. Wang, L. D. Nelin, Y. Yao, R. Matta, M. E. Manson, R. S. Baliga, X. Meng, C. V. Smith, J. A. Bauer, et al. 2006. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J. Exp. Med. 203: 131-140.
24. Chi, H., S. P. Barry, R. J. Roth, J. J. Wu, E. A. Jones, A. M. Bennett, and R. A. Flavell. 2006. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc. Natl. Acad. Sci. USA 103: 2274-2279.
25. Hammer, M., J. Mages, H. Dietrich, A. Servatius, N. Howells, A. C. Cato, and R. Lang. 2006. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J. Exp. Med. 203: 15-20.
26. Salojin, K. V., I. B. Owusu, K. A. Millerchip, M. Potter, K. A. Platt, and T. Oravecz. 2006. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J. Immunol. 176: 1899-1907. (Pubitemid 43134335)
27. Dorfman, K., D. Carrasco, M. Gruda, C. Ryan, S. A. Lira, and R. Bravo. 1996. Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 13: 925-931. (Pubitemid 26329078)
28. Kuhn, R., J. Lohler, D. Rennick, K. Rajewsky, and W. Muller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274. (Pubitemid 23320290)
29. Guo, L., Z. Song, M. Li, Q. Wu, D. Wang, H. Feng, P. Bernard, A. Daugherty, B. Huang, and X. A. Li. 2009. Scavenger receptor BI protects against septic death through its role in modulating inflammatory response. J. Biol. Chem. 284: 19826-19834.
30. Dellinger, R. P., M. M. Levy, J. M. Carlet, J. Bion, M. M. Parker, R. Jaeschke, K. Reinhart, D. C. Angus, C. Brun-Buisson, R. Beale, et al. 2008. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36: 296-327.
31. Rivers, E., B. Nguyen, S. Havstad, J. Ressler, A. Muzzin, B. Knoblich, E. Peterson, and M. Tomlanovich. 2001. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 345: 1368-1377.
32. Brierley, J., J. A. Carcillo, K. Choong, T. Cornell, A. Decaen, A. Deymann, A. Doctor, A. Davis, J. Duff, M. A. Dugas, et al. 2009. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit. Care Med. 37: 666-688.
33. Chen, P., J. Li, J. Barnes, G. C. Kokkonen, J. C. Lee, and Y. Liu. 2002. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J. Immunol. 169: 6408-6416. (Pubitemid 36903490)
34. Suzuki, Y., C. Lanner, J. H. Kim, P. G. Vilardo, H. Zhang, J. Yang, L. D. Cooper, M. Steele, A. Kennedy, C. B. Bock, et al. 2001. Insulin control of glycogen metabolism in knockout mice lacking the muscle-specific protein phosphatase PP1G/RGL. Mol. Cell Biol. 21: 2683-2694.
35. Bogdan, C. 2001. Nitric oxide and the immune response. Nat. Immunol. 2: 907-916.
36. Nelin, L. D., X. Wang, Q. Zhao, L. G. Chicoine, T. L. Young, D. M. Hatch, B. K. English, and Y. Liu. 2007. MKP-1 switches arginine metabolism from nitric oxide synthase to arginase following endotoxin challenge. Am. J. Physiol. Cell Physiol. 293: C632-C640.
37. Couper, K. N., D. G. Blount, and E. M. Riley. 2008. IL-10: the master regulator of immunity to infection. J. Immunol. 180: 5771-5777.
38. Redpath, S., P. Ghazal, and N. R. Gascoigne. 2001. Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol. 9: 86-92. (Pubitemid 32155327)
39. Bogdan, C., Y. Vodovotz, and C. Nathan. 1991. Macrophage deactivation by interleukin 10. J. Exp. Med. 174: 1549-1555.
40. Reddy, R. C., G. H. Chen, M. W. Newstead, T. Moore, X. Zeng, K. Tateda, and T. J. Standiford. 2001. Alveolar macrophage deactivation in murine septic peritonitis: role of interleukin 10. Infect. Immun. 69: 1394-1401.
41. Sewnath, M. E., D. P. Olszyna, R. Birjmohun, F. J. ten Kate, D. J. Gouma, and T. van Der Poll. 2001. IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J. Immunol. 166: 6323-6331.
42. Steinhauser, M. L., C. M. Hogaboam, S. L. Kunkel, N. W. Lukacs, R. M. Strieter, and T. J. Standiford. 1999. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J. Immunol. 162: 392-399.
43. Sadikot, R. T., H. Zeng, A. C. Azim, M. Joo, S. K. Dey, R. M. Breyer, R. S. Peebles, T. S. Blackwell, and J. W. Christman. 2007. Bacterial clearance of Pseudomonas aeruginosa is enhanced by the inhibition of COX-2. Eur. J. Immunol. 37: 1001-1009.
44. Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340: 448-454.
45. Feingold, K. R., M. K. Serio, S. Adi, A. H. Moser, and C. Grunfeld. 1989. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology 124: 2336-2342. (Pubitemid 19132035)
46. Nonogaki, K., A. H. Moser, K. R. Feingold, and C. Grunfeld. 1994. Alpha-adrenergic receptors mediate the hypertriglyceridemia induced by endotoxin, but not tumor necrosis factor, in rats. Endocrinology 135: 2644-2650.
47. Eichbaum, E. B., H. W. Harris, J. P. Kane, and J. H. Rapp. 1991. Chylomicrons can inhibit endotoxin activity in vitro. J. Surg. Res. 51: 413-416.
48. Harris, H. W., C. Grunfeld, K. R. Feingold, and J. H. Rapp. 1990. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J. Clin. Invest. 86: 696-702.
49. Ali, N. A., J. M. O'Brien, Jr., K. Dungan, G. Phillips, C. B. Marsh, S. Lemeshow, A. F. Connors, Jr., and J. C. Preiser. 2008. Glucose variability and mortality in patients with sepsis. Crit. Care Med. 36: 2316-2321.
50. Hirshberg, E., G. Larsen, and H. Van Duker. 2008. Alterations in glucose homeostasis in the pediatric intensive care unit: hyperglycemia and glucose variability are associated with increased mortality and morbidity. Pediatr. Crit. Care Med. 9: 361-366.
51. Van den Berghe, G., A. Wilmer, G. Hermans, W. Meersseman, P. J. Wouters, I. Milants, E. Van Wijngaerden, H. Bobbaers, and R. Bouillon. 2006. Intensive insulin therapy in the medical ICU. N. Engl. J. Med. 354: 449-461.
52. Wu, J. J., R. J. Roth, E. J. Anderson, E. G. Hong, M. K. Lee, C. S. Choi, P. D. Neufer, G. I. Shulman, J. K. Kim, and A. M. Bennett. 2006. Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metab. 4: 61-73.
53. Bhavsar, P., M. Hew, N. Khorasani, A. Torrego, P. J. Barnes, I. Adcock, and K. F. Chung. 2008. Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax 63: 784-790.
54. Sutherland, E. R., E. Goleva, M. Strand, D. A. Beuther, and D. Y. Leung. 2008. Body mass and glucocorticoid response in asthma. Am. J. Respir. Crit. Care Med. 178: 682-687.